Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav - Integrase inhibitor - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-11-03 11:26:24 Intel Viiv Integrase inhibitors Organofluorides Pfizer Biology Pharmacology Dolutegravir Shionogi Pharmaceutical industry Pharmaceutical sciences ViiV Healthcare GlaxoSmithKline		Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav Add to Reading List Source URL: shionogi616.tew-staging.com Download Document from Source Website File Size: 94,97 KB Share Document on Facebook

	Superior drug derivatives via late stage hydroxylation Microsomal and microbial biotransformation of drugs There is increasing focus on thorough investigation of drug metabolites, exemplified by Pfizer’s routine biocat DocID: 1v0tF - View Document
	Plasma Protein Binding: Friend or Foe in Drug Discovery? Kevin Beaumont and Tristan Maurer Pharmacokinetics, Dynamics and Metabolism Pfizer Worldwide Research and Development Memorial Drive, Cambridge DocID: 1uQg4 - View Document
	Dárci 2010 Finanční dary SAZKA Praha ROCHE Praha Pfizer s.r.o. Praha Novartis s.r.o., Praha DocID: 1tU5V - View Document
	Clonazepam 2 mg costo. Getting to know Microsoft Money for Lconazepam Clonazepam 2 mg costo takes only pfizer terramycin la few minutes, and its time well spent. Hutton CThe Meteorology And Climate Of Tropical A DocID: 1tffN - View Document
	JP Morgan Healthcare Conference Advancing Differentiated High Value Products Mikael Dolsten, M.D., Ph.D. President Worldwide R&D January 13, 2015 DocID: 1t2Pn - View Document